CUE
NASDAQ HealthcareCue Biopharma, Inc. - Common Stock
Biotechnology
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $27.79 |
|---|---|
| 成交量 | 192,523 |
| 市值 | 116.73M |
| 贝塔系数 | 2.460 |
| RSI（14日） | 54.0 |
| 200日均线 | $17.70 |
| 50日均线 | $27.91 |
| 52周最高 | $45.50 |
| 52周最低 | $4.98 |
| Forward P/E | -57.90 |
| Price / Book | 4.19 |
🎯 投资策略评分
CUE 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (94/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CUE in your text
粘贴任何文章、记录或帖子 — 工具将提取 CUE 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.